Celldex Therapeutics Inc (NASDAQ: CLDX) kicked off on Friday, down -7.99% from the previous trading day, before settling in for the closing price of $17.15. Over the past 52 weeks, CLDX has traded in a range of $16.40-$47.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 43.00% over the past five years. While this was happening, its average annual earnings per share was recorded -33.83%. With a float of $64.70 million, this company’s outstanding shares have now reached $66.37 million.
Let’s look at the performance matrix of the company that is accounted for 186 employees. In terms of profitability, gross margin is 77.61%, operating margin of -2778.89%, and the pretax margin is -2248.76%.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.54%, while institutional ownership is 109.63%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.12% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Take a look at Celldex Therapeutics Inc’s (CLDX) current performance indicators. Last quarter, stock had a quick ratio of 18.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 149.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.93 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Celldex Therapeutics Inc (NASDAQ: CLDX) saw its 5-day average volume 1.02 million, a positive change from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 14.42%. Additionally, its Average True Range was 1.20.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 2.35%, which indicates a significant decrease from 5.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.48% in the past 14 days, which was higher than the 54.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.21, while its 200-day Moving Average is $29.37. Nevertheless, the first resistance level for the watch stands at $16.71 in the near term. At $17.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.26. If the price goes on to break the first support level at $15.15, it is likely to go to the next support level at $14.53. The third support level lies at $13.60 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
The company with the Market Capitalisation of 1.05 billion has total of 66,384K Shares Outstanding. Its annual sales at the moment are 7,020 K in contrast with the sum of -157,860 K annual income. Company’s last quarter sales were recorded 1,180 K and last quarter income was -47,090 K.
